Please assess the completion status of the following clinical trial:

Trial Title: Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed B-cell non-Hodgkin lymphoma (NHL), including any of the following:~  * Marginal zone lymphoma~ * Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma)~ * Follicular lymphoma~ * Mantle cell lymphoma~* Relapsed or refractory disease after ≥ 1 prior therapy~* Patients with rituximab-refractory disease (defined as having less than a partial response to the prior rituximab-containing regimen) or rituximab-sensitive disease (defined as having a complete response or partial response to the last rituximab-containing regimen \[provided it has been ≥ 3 months since the last dose of rituximab\]) are eligible.~* Age \>18 years.~* Eastern Cooperative Oncology Group (ECOG)performance status 0-2.~* Patients must have normal organ and marrow function as defined below:~  * Absolute neutrophil count ≥ 1000/μL~ * Platelets ≥ 75,000/μL~ * Total bilirubin ≤ 2.0 X institutional upper limit of normal~ * AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal~ * Creatinine ≤ 2.0 mg/dL~* Patients who have relapsed after stem cell transplant are eligible for this trial.~* Patients with active Hepatitis B infection are not eligible.~* Non-pregnant and non-nursing. Women of child bearing potential and men must agree to use contraception prior to study entry and for duration of study participation.~* Must possess the ability to understand and the willingness to sign a written informed consent document.~Phase II~-Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension \>10 mm or in the case of Waldenstrom's macroglobulinemia, the presence of an IgM paraprotein level 2x the upper limit of normal.~Exclusion Criteria:~* Must be recovered from all toxicities from prior therapy or radiation (excluding alopecia).~* No known CNS lymphoma.~* History of documented human anti-globulin antibodies.~* No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations.~* HIV-positive patients.~* Pregnant women.~* Patients with secondary malignancies with exception of non-melanomatous skin cancers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I (Type: EXPERIMENTAL): Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
- Phase II (Type: EXPERIMENTAL): Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete